Canadian biopharmaceutical company Liminal BioSciences Inc specializes in the development of small molecule drug therapeutics to treat inflammatory, fibrotic, and metabolic diseases and is situated in Laval, Canada. Their lead candidate drug, fezagepras, completed its Phase I clinical trial, aiming to treat idiopathic pulmonary, liver, cardiac, or skin fibrosis, among respiratory diseases, by using fezagepras or derivatives. The company has preclinical-stage antagonist candidate programs that include G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1.